Mucin-4 (Muc4) is a large cell surface glycoprotein implicated in the protection and lubrication of epithelial structures. Previous studies suggest that aberrantly expressed Muc4 can influence the adhesiveness, proliferation, viability and invasiveness of cultured tumor cells, as well as the growth rate and metastatic efficiency of xenografted tumors. Although it has been suggested that one of the major mechanisms by which Muc4 potentiates tumor progression is via its engagement of the ErbB2/HER2 receptor tyrosine kinase, other mechanisms exist and remain to be delineated. Moreover, the requirement for endogenous Muc4 for tumor growth progression has not been previously explored in the context of gene ablation. To assess the contribution of endogenous Muc4 to mammary tumor growth properties, we first created a genetically engineered mouse line lacking functional Muc4 (Muc4 ko ), and then crossed these animals with the NDL (Neu DeLetion mutant) model of ErbB2-induced mammary tumorigenesis. We observed that Muc4 ko animals are fertile and develop normally, and adult mice exhibit no overt tissue abnormalities. In tumor studies, we observed that although some markers of tumor growth such as vascularity and cyclin D1 expression are suppressed, primary mammary tumors from Muc4 ko /NDL female mice exhibit similar latencies and growth rates as Muc4 wt /NDL animals. However, the presence of lung metastases is markedly suppressed in Muc4 ko /NDL mice. Interestingly, histological analysis of lung lesions from Muc4 ko /NDL mice revealed a reduced association of disseminated cells with platelets and white blood cells. Moreover, isolated cells derived from Muc4 ko /NDL tumors interact with fewer blood cells when injected directly into the vasculature or diluted into blood from wild type mice. We further observed that blood cells more efficiently promote the viability of non-adherent Muc4 wt /NDL cells than Muc4 ko /NDL cells. Together, our observations suggest that Muc4 may facilitate metastasis by promoting the association of circulating tumor cells with blood cells to augment tumor cell survival in circulation.
INTRODUCTION
Metastasis is a fundamentally complex and inefficient process where a minority of cancer cells will migrate from the primary tumor, invade the vasculature, survive the harsh conditions of vascular transit and colonize new tissues. 1 Consequently, few metastases arise despite the potential for tumors to shed millions of cells into circulation. [1] [2] [3] Nevertheless, metastatic disease is the leading cause of cancer-associated mortality and is strongly associated with relapse following therapeutic intervention. [4] [5] [6] As such, there is an urgent need to understand the molecular determinants of metastasis to improve patient outcomes and optimize clinical disease management.
Mucin-4 (Muc4) is a large cell surface glycoprotein, composed of a heavily O-glycosylated extracellular alpha subunit and a membrane-anchored beta subunit that normally functions to lubricate and protect apical epithelial surfaces. 7 Several studies indicate that Muc4 augments cellular properties associated with the metastatic potential of carcinoma cells, and we have demonstrated that Muc4 protein is elevated in metastatic lesions compared with patient-matched primary breast tumors, strongly suggesting that Muc4 confers an advantage to metastasizing tumor cells. 8 Although the precise mechanisms by which Muc4 contributes to metastasis remain to be delineated, there are several plausible hypotheses. The bulky alpha subunit of Muc4 may promote dislodgement of tumor cells from the primary mass, enhancing invasion into the surrounding matrix. Indeed, Muc4 has been reported to enhance the motility, invasiveness and metastatic capacity of pancreatic and melanoma cancer cells, [9] [10] [11] [12] [13] inhibit cellto-cell or cell-to-matrix interactions, 9, 14 and promote the EMT (epithelial-to-mesenchymal transition) upon overexpression in prostate cancer cells. 12, 15 Muc4 may also prepare tumor cells for hematogenous dissemination. The alpha subunit could serve as a physical barrier to attachment and as a sensor of biochemical changes in the extracellular milieu, reflected by its protective role in secretory epithelium. 7, 16 The alpha subunit may likewise enable movement of tumor cells into the vasculature via glycan-directed interactions with soluble factors and adhesion molecules. Along these lines, Muc4-galectin complexes promote endothelial adhesion in a pancreatic cancer model, 17 an interaction that may also facilitate extravasation at the metastatic site and inhibit suspensioninduced cell death, or anoikis. 18, 19 Interestingly however, our group established that Muc4 overexpression not only promotes cell survival in growth factor depleted conditions and inhibits anoikis, but that these effects occur independently of the alpha subunit. 20 Taken together, these observations suggest that Muc4 upregulation may be a multifaceted adaptation that permits tumor cell survival during vascular transit to facilitate colonization at distant sites.
The most well documented role of Muc4 in the context of cancer is its capacity to modulate receptor tyrosine kinase signaling. In particular, Muc4 augments ErbB2/HER2 receptormediated signaling in breast, melanoma, ovarian and pancreatic cancer cell models. [21] [22] [23] [24] [25] These findings are significant in that ErbB2/HER2 correlates with substantially lower overall survival rates, shorter disease-free intervals and increased incidence of metastasis. 26, 27 However, the contribution of endogenous Muc4 to ErbB2-mediated cancer onset and progression has not been explored. Here we employ a Muc4 knockout mouse to demonstrate Muc4 is dispensable for the efficient growth of ErbB2induced primary mouse mammary tumors, but significantly enhances the occurrence of lung metastases. We further demonstrate that although endogenous Muc4 is sufficient to promote survival of tumor cells in suspension conditions, overall viability is greatly enhanced in the presence of platelets and immune cells. These observations firmly establish Muc4 as a mediator of metastasis, likely acting as a critical factor during vascular transit.
RESULTS
Creation and characterization of Muc4 tm1Unc mutant mice Muc4-deficient mice were generated using a targeting vector that replaces 981 bp of genomic sequence containing the starting methionine in exon 1 with a reverse-oriented floxed MC1neo cassette, and that includes a PGK-TK cassette for negative selection (Figure 1a ). Muc4 tm1Unc founder animals were generated via homologous recombination on a mixed SV129:FvB/NJ background, and progeny were back-crossed at least 10 generations onto the FvB/NJ strain prior to phenotypic analysis. Mice heterozygous for Muc4 were interbred to generate all genotypes, designated here as wild type (Muc4 wt ), heterozygous (Muc4 het ) and knockout (Muc4 ko ). Muc4 disruption was confirmed at the transcript (Supplementary Figure 1A ) and protein levels (Supplementary Figure 1B) . No discernable effects of Muc4 disruption on viability, breeding or lactation were observed, and no differences in mammary gland architecture were noted between genotypes in adult virgin mammary glands (Supplementary Figure 1C ).
Muc4 disruption does not delay mammary tumor onset or inhibit tumor growth
Previous studies indicate that Muc4 physically interacts with ErbB2 21 to augment its signaling either directly 20 or indirectly via stabilization of ErbB2-ErbB3 receptor heterodimers. 23 Accordingly, Muc4 may potentiate ErbB2 pro-tumorigenic signaling to enhance tumorigenesis. To explore this postulate, we interbred Muc4 tm1Unc FvB/NJ with a well-characterized mouse model in which an activated rat c-erbB2/neu allele (Neu DeLetion mutant, NDL) transgene is under the control of the MMTV (mouse mammary tumor virus promoter). 28 The MMTV-NDL mouse forms highly metastatic multifocal tumors at~20 weeks of age. 28 Absence of Muc4 protein in mammary tumors of Muc4 ko /NDL relative to Muc4 wt /NDL and Muc4 het /NDL female mice was confirmed by immunohistochemistry ( Figure 1b ).
Interestingly, Muc4 wt /NDL tumors exhibited variable protein expression, with adjacent normal and stromal tissues exhibiting the most robust immunoreactivity for Muc4 beta when compared with the primary mass ( Figure 1c ). These data are consistent with our previous findings in human tissues, where Muc4 protein expression is downregulated in primary breast tumors relative to matched normal tissue or lymph node metastases. 8 Muc4 also is not specifically elevated in tumor cells exhibiting signs of invasiveness (that is, aligned at the leading edge of the tumor; see Figure 1c right panel inset, closed arrowheads), supportive of a relatively minor role for Muc4 during primary tumor growth and local invasion.
In support of this, we observed that Muc4 wt /NDL, Muc4 het /NDL and Muc4 ko /NDL tumors emerge and grow with remarkably similar kinetics; no significant differences were apparent among genotypes in latency to tumor formation ( Supplementary Figure 2A) , the time necessary for tumors to reach an approximate diameter of 20 mm (Figure 2a ), average growth rates ( Figure 2b ), or in overall tumor burden ( Figure 2c ). The histopathology of Muc4 wt / NDL and Muc4 ko /NDL tumors were generally comparable, appearing as well-differentiated, heterogeneous mammary adenocarcinomas characteristic of the NDL model 28, 29 (Figure 2d ). Notably, Muc4 ko /NDL lesions tended to be more cystic when compared with Muc4 wt /NDL tumors (Supplementary Figure 2B ), although this feature was not statistically significant (P = 0.09).
The similar growth rates between genotypes could be explained by relative rates of cell turnover, as Muc4 wt /NDL tumors had higher levels of both proliferation (Figure 2e ) and apoptosis ( Figure 2f ) when compared to Muc4 ko /NDL tumors. Interestingly, Muc4 ko /NDL tumors expressed considerably lower levels of cyclin D1 ( Figure 3a ) and phosphorylated tumor cell-expressed vascular endothelial growth factor receptor 2 (Figure 3a ), reflective of reduced angiogenic factor production. Consistent with the suppression of angiogenic signaling, we found a significant reduction in Muc4 ko /NDL tumor vascularity as indicated by poor immunoreactivity for the endothelial marker, CD31 ( Figure 3b ).
Muc4 disruption suppresses metastasis
Our previous studies indicate that Muc4 protein is upregulated in lymph node metastatic lesions relative to patient-matched primary breast tumors, 8 raising the possibility that Muc4 actively contributes to the metastatic process. Therefore, we analyzed lung tissue by gross morphology and histology ( Figure 4a ) and observed that, indeed, Muc4 ko /NDL tumors are less metastatic than Muc4 wt /NDL and Muc4 het /NDL, despite primary lesions having been carried for similar amounts of time and to the same endpoint ( Figure 4b ). Not only did Muc4 expression enhance the penetrance of lesions to the lung (Figure 4b ), it also substantially increased the total metastatic burden ( Figure 4c ) and extent of colonization to the lung parenchyma ( Figure 4d ).
We next examined whether Muc4 expression affects prometastatic factors that may permit the survival, migratory or invasive capacities of tumor cells. We found that Muc4 deletion correlates with reductions in proteins commonly associated with EMT in primary tumors, including twist 1/2 and vimentin (Supplementary Figure 3A) . Lung metastases exhibited similar trends, where vimentin is elevated in Muc4 wt /NDL lesions compared with Muc4 ko /NDL (Supplementary Figure 3B ). While we anticipated that reductions in EMT-associated proteins would attenuate migration, we observed no differences in the abilities of ex vivo dissociated tumor cells to migrate in a transwell assay (Supplementary Figure 3C ). Taken together, these data suggest that Muc4 markedly modifies tumor protein expression but that these alterations are not sufficient to elevate migratory capacity.
Muc4 may facilitate metastasis via physical interactions with blood cells Disrupted VEGFR signaling may reduce both the abundance and permeability of the tumor-associated vascular bed 30 and therefore the relative efficiency of NDL cells to access essential networks for metastasis. Accordingly, we evaluated whether Muc4 benefited tumor cells even when given equal access to vasculature. Indeed, Muc4 wt /NDL cells instilled directly to the lateral tail vein generated more metastatic lesions to the lung compared with Muc4 ko /NDL cells (Figures 5a and b ). When lesions were stratified by type (colonized, emboli), we found a significant difference in the capacity of Muc4 wt /NDL cells to colonize the lung parenchyma The strategy employed to functionally delete the murine Muc4 gene is depicted. Homologous recombination of the targeting vector with genomic Muc4 replaces exon 1 with a neomycin resistance cassette (Neo) transcribed in the direction indicated by the arrow; thymidine kinase (TK) was included in the targeting vector for negative selection. Insertion of Neo introduced a Pst1 restriction site that was used to confirm knockout in ES cells by Southern blot (not shown) using the probe indicated by the dotted box. The schematic is not shown to scale. (b) Functional deletion of Muc4 in NDL mammary tumor tissue was confirmed by immunohistochemistry using an antibody that detects the beta subunit of Muc4. Representative images were selected from at least three biological replicates. (c) Representative images selected from at least three biological replicates highlighting the variability in the level of Muc4 expression between the primary mass and its adjacent tissues. Muc4 protein expression was detected as described above. Normal adjacent mammary ducts (left panel) and stromal tissues (right panel) exhibit robust expression of Muc4. Boxed regions have been expanded to show detail (insets). Muc4 positivity was also noted in blood vessels (right inset, asterisk), as previously described. 8 ( Figures 5c and d) . It is likely that Muc4 confers a significant survival advantage to tumor cells, reflected in the enhanced viability of Muc4 wt /NDL cells when subjected to an anoikis assay in vitro (Supplementary Figure 4A ). Finally, we observed that Muc4 may be specifically upregulated during vascular transit, as its expression appeared to be strongest in tumor cells found either within or in close proximity to vascular lumens and reduced in established lung lesions ( Figure 5e ).
Disseminated tumor cells are known to travel as complex aggregates, consisting of clusters of cancer cells, platelets and other blood cells. These microthrombi are thought to critically improve tumor cell survival and extravasation by promoting longterm adhesion and arrest within microvasculature, while shielding tumor cells from the shear stress imposed during transit in circulation. 1 To explore whether some of the pro-metastatic effects of Muc4 could arise from tumor cell interactions with platelets and other blood cell components, we first histologically assessed the association of tumor cells with blood cells in lung lesions. By standard hematoxylin and eosin staining, we noted a substantial increase in the abundance of platelets and immune cells within Muc4 wt /NDL relative to Muc4 ko /NDL emboli (H&E, Figure 6a ; arrowheads), further verified by specific staining for macrophages (F4/80) and platelets (CD41, Figure 6a ). A majority of the cells were immunoreactive for CD41, suggesting an abundance of platelets and/or hematopoietic progenitors 31 although it is unclear whether they infiltrated the lesion locally at the lung or if they were a component of the original circulating microthrombi. Nevertheless, Muc4 wt /NDL lesions were more proliferative when compared with Muc4 ko /NDL lesions (phosoho-histone H3, Figure 6a ), a feature which may partially account for differences in colonizing ability.
To explore whether the presence of Muc4 enhances the interaction of tumor and blood cells, we developed an in vitro suspension assay in which blood cells were admixed with either Muc4 wt /NDL or Muc4 ko /NDL tumor cells. After 1.5 h and 24 h, we noted significant increases in the number of blood cells that were closely associated with individual Muc4 wt /NDL tumor cells or tumor cell aggregates (Figure 6b and Supplementary Movies 1 and 2; Po 0.05). Importantly, we found similar interactions to occur in vivo, where tail vein injected Muc4 wt /NDL cells were more likely to be found with large clusters of blood cells (Figure 6c ).
It is likely the physical interaction of Muc4 with blood cells is requisite for efficient tumor cell viability, suggested by enhanced survival (Figure 6d and Supplementary Figure 4B ) and sphereforming capacity (Supplementary Figure 4C) only when Muc4 wt / NDL cells were directly co-cultured with blood cells. These effects relied solely on the status of Muc4 in the tumor cell, as blood cells derived from Muc4 ko and Muc4 wt mice were equally capable of improving the viability of suspension cultured Muc4 wt /NDL cells (Figure 6d ).
DISCUSSION
In the context of cancer, Muc4 has been shown to initiate signaling cascades through interactions with members of the ErbB family of receptor tyrosine kinases. In particular, the association of Muc4 with ErbB2/HER2 enforces receptor complex stability at the plasma membrane and potentiates tyrosine phosphorylation of ErbB2 to augment cellular differentiation, proliferation and survival. 7, 21, 23 We now provide appreciable insight into Muc4 biology by establishing its primary role in the malignant progression of ErbB2-overexpressing mammary carcinomas. Although we found that Muc4 is dispensable for primary tumor growth, it significantly augments the efficiency of metastasis, reflected by an increased occurrence, burden and colonization of secondary lesions in the lung. We provide further mechanistic insight that Muc4 engages a complex survival strategy that is likely to encompass both intrinsic signaling and intercellular interactions during the hematogenous dissemination of tumor cells.
These findings are significant, as vascular transit represents a particularly vulnerable stage of metastasis, where tumor cells must remain viable under suspension conditions, withstand significant shear stresses and evade immune surveillance. 1 Disseminated tumor cells are thought to interact with immune cells and platelets, 1,32 which may potentiate their demise 33 or promote their survival. [34] [35] [36] For example, a recent study demonstrated metastatic colonization of breast cancer cells to the lung was aided by the formation of extracellular nets by neutrophils, ostensibly facilitating expansion of lodged tumor cells. 37 Recruitment of neutrophils and other leukocytes may be accomplished by the formation of platelet-tumor cell aggregates, which would be more likely to become entrapped in microvessels than individual cancer cells. 1 In turn, clot formation may enhance survival, early niche creation and extravasation via recruitment of macrophages to the site of arrest. 35 The association of platelets with disseminated cancer cells is so pervasive that platelets or platelet mimics are currently being engineered as anti-cancer therapeutics to deliver cytotoxic agents to tumor cells. [38] [39] [40] On the other hand, inhibition of platelet Figure 5 . Muc4 deletion impairs the metastatic capacity of tail vein injected NDL cells. Pooled (n = 4 independent biological sources per line) primary Muc4 wt /NDL and Muc4 ko /NDL tumor cells were instilled into the lateral tail vein of FVB wt mice (n = 6). Tissues (lungs, digestive tract, liver, spleen, uterus, brain) were collected 28 d later, fixed in 4% paraformaldehyde and evaluated for the appearance of gross metastasis. Only lungs were found to contain gross lesions, more readily visible by carmine alum stain (a). Scale bar = 1 mm. (b-d). H&E-stained sections were used to quantify the occurrence of metastatic lesions. The total number of metastases (b) and the frequency of colonized lesions (c) formed in the lungs of mice injected with Muc4 wt /NDL cells was significantly increased compared with those receiving Muc4 ko /NDL cells. There was a modest reduction in the frequency of emboli formed by Muc4 ko /NDL cells (P = 0.086). Representative H&E-stained sections are presented in aggregation 32, 41 or immune cell function [35] [36] [37] is sufficient to impede metastasis. Our observations strongly suggest that Muc4 is an essential component of such blood cell-tumor cell interactions, reflected by the association of platelets and immune cells with both circulating and lodged Muc4 wt /NDL cells. Further to this, our in vitro studies suggest this interaction enhances the survival of Muc4-expressing cells under suspension conditions, as might be expected during vascular transit.
These data impart additional complexity to our understanding of Muc4. Previous reports imply that Muc4 protects circulating tumor cells from immune destruction 42 as a result of the ability of its bulky glycosylated extracellular region to mask surface epitopes and inhibit immune recognition. 43 Although our data do not directly refute or support this model, we found no decrease in the survival in Muc4 ko /NDL cells when co-cultured with blood cells, suggesting that viability is not based on immune destruction per se. It is worth noting a recent study in which Muc4 was enhanced in both chronic and acute models of inflammation, 44 lending further credence to the postulate that Muc4 acts as a critical survival factor during periods of heightened immune response.
Beyond demonstrating a pro-survival function of Muc4, we provide evidence that it is required for robust tumor angiogenesis. Along these lines, Muc4 ko /NDL tumors exhibited reduced phosphorylation of VEGFR2R and blood vessel formation, suggesting that differences in the rate of metastasis may partially depend on the relative abundance of vessels in which to invade. Previous reports indicate that Muc4 is expressed by differentiated endothelial cells, is associated with the luminal surfaces of blood vessels 8, 45, 46 and when knocked down attenuates VEGF expression and angiogenesis. 47 Whether Muc4 presence in endothelial or epithelial cells is essential or permissive for blood vessel formation has yet to be established. However, its specific upregulation in endothelium during intermediate stages of wound-induced angiogenesis, 46 and its association with epithelium-derived regulators such as ErbB2, 48, 49 β-catenin and VEGF, 47 point to possible roles. Although our current model precludes extensive investigation of the differential requirements for epithelial and endothelial Muc4 in angiogenesis, future cross-transplantation studies in which Muc4 replete epithelium is transplanted into knockout stromal tissue and vice versa may yield valuable insight.
We also found expression of proteins implicated in EMT (twist and vimentin) to be markedly attenuated in the absence of Muc4. Although we were unable to demonstrate a significant difference in migratory capacity with a loss of Muc4, the marked reduction in both metastasis and in the expression of key metastatic drivers suggest it as a potential therapeutic target, especially in the context of HER2-positive breast carcinomas.
MATERIALS AND METHODS

Generation of Muc4 tm1Unc mice
The University of North Carolina (UNC) Animal Models Core (Chapel Hill, NC, USA) generated Muc4-deficient mice via homologous recombination in mouse embryonic stem cells. In brief, a 129SvEv BAC mouse genomic library was screened for Muc4 genomic sequences containing exon 1 using two Muc4 cloned sequences (a 430 bp fragment from 6824 to 7254 and a 347 bp fragment from 10716-11063 of sequence NM_080457). Short-and long-arm homologous fragments were cloned from the Muc4 genomic BAC into targeting vector pOSdupdel6142-SA vector to generate the targeting vector pOSdupdel6142-Muc4, which was electroporated into 129SvEv embryonic stem (ES) cells. Embryonic stem cell clones with the targeted recombination event were selected with Geneticin and ganciclovir, screened by polymerase chain reaction and confirmed by Southern blot (not shown) prior to injection into FvB/NJ blastocysts to generate chimeric founders. Founder males from identified embryonic stem cell lines were crossed to FvB/NJ female mice to yield Muc4 tm1Unc mice heterozygous for the targeted allele, and these were then crossed to initiate Muc4 tm1Unc lines. Nomenclature was developed in accordance with the International Committee on Standardized Genetic Nomenclature for Mice as implemented by the Mouse Genomic Nomenclature Committee. Loss of Muc4 protein was confirmed with a Muc4 mouse monoclonal antibody to the beta subunit as described. 8 Generation of Muc4/NDL mice All experimental protocols were approved by the IACUC of the University of California, Davis, CA, USA. The NDL mouse model has previously been described. 29 Muc4 het females were crossed with NDL males to generate Muc4 wt /NDL, Muc4 het /NDL and Muc4 ko /NDL genotypes. Genotypes were confirmed using polymerase chain reaction by commercial vendor (Muc4, Transnetyx, Cordova, TN, USA) or in house (NDL) using primers for Muc4 (Fwd-AGCTAAAGAATGTGGCCATAAAGGA; Rvs-CGTTCCCACCATCCTC CAAAA), neomycin (Fwd 5'-GGGCGCCCGGTTCTT-3'; Rvs 3'-CCTCGTCCTG CAGTTCATTCA-5') and NDL (Fwd 5'-TTCCGGAACCCACATCAG-3'; Rvs-3'-GTTTCCTGCAGCAGCCTA-5').
Quantitative polymerase chain reaction
Tissue was homogenized in Trizol reagent (Thermo Fisher Scientific; Waltham, MA, USA) by Dounce homogenizer per manufacturer's guidelines. Total RNA was purified using an RNA purification kit (Thermo, Cat# 12183025) and complementary DNA prepared as described. 50 Quantitative polymerase chain reaction was carried out as described 51 using probe sets specific for Muc4 (mm0046688_m1) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 435293E) used for normalization.
Tumor monitoring and analysis
Mammary tumors were palpated twice weekly in female NDL mice commencing at 12 weeks of age by a single investigator partially blinded to genotypes. As tumors form in multiple mammary glands in the NDL model, 29 the growth rates of all tumors were recorded by caliper measurements. The leading tumor was allowed to reach a maximum diameter of 20 mm, at which time the mice were euthanized by CO 2 asphyxiation, lungs collected and fixed for whole-mount analysis and tumors bisected and randomly allocated to either fixation in 10% neutral buffered formalin and paraffin embedding or further dissociation for in vitro studies. Animals with illness arising independent of their tumors that required sacrifice prior to the tumor reaching pre-determined criteria were excluded from analyses.
Histology and Immunohistochemistry
Histological analysis was performed for a randomly selected subset of the most advanced tumors (n ⩾ 7). H&E-stained sections were prepared from Muc4 wt /NDL and Muc4 ko /NDL tumors using previously described methods, 52 with analysis of tumor features carried out blinded by a licensed pathologist. Immunohistochemistry was performed essentially as described 50 with the substitution of 10% normal goat serum for protein blocking, Bloxall for blocking endogenous peroxidase (Vector Laboratories, Burlingame, CA, USA), DAB as the chromogen (Vector) and tris-buffered saline with 0.1% tween as the buffer for phosphorylated antibodies. Antibodies used for immunohistochemistry are listed in Supplementary  Table 1 . Tumor sections were prepared as an array (n = 3-4 tumors of the same genotype on a single slide) or as individual tumors from a single source. Where used, staining intensities were scored with the scale: 0 = negative, 1 = weak, 2 = moderate and 3 = strong with the accuracy of scoring confirmed by a blinded observer. An internal negative control (no primary antibody) was included with each trial.
Lung analysis
Lungs were inflated with phosphate-buffered saline (PBS), fixed in formalin for 24 h and stained in carmine alum as described. 50 Gross lesions were imaged under a dissecting microscope (Zeiss Stemi 2000-C; Axiocam ERc/ 5 s) and further dissected for confirmation by histology. Microlesions were evaluated separately by histology of four-step serial sections (5 μm, n = 3) taken at 40-50 μm intervals.
Tail vein injections
Pooled primary Muc4 wt /NDL or Muc4 ko /NDL cells (n = 4 per genotype; 5 × 10 5 in 200 μl PBS) were instilled under isoflurane anesthesia to the lateral tail vein of 9-week-old FvB/NJ female mice (Jackson Laboratory, Bar Harbor, ME, USA). Blood and tissues (lung, liver, spleen, uterus, brain, kidney, digestive tract) were collected 3d (n = 4/line) and 28 d (n = 6/line) later for circulating tumor cell assays and analysis of metastasis, respectively. Mice were randomly assigned to both treatments and time of sacrifice and were caged as mixed cohorts.
Cell culture
Cells were maintained in Dulbecco's Modified Eagle's medium+10% fetal bovine serum (FBS, Axenia Biologix, Dixon, CA, USA) and penicillin/ streptomycin (Gibco, Waltham, MA, USA) at 37°C under 10% CO 2 and were were routinely passaged using 0.05% typsin-EDTA (Gibco). Primary NDL tumor cells were dissociated by enzymatic and mechanical methods essentially as described for normal mammary tissue 52 from Muc4 wt /NDL (n = 4) and Muc4 ko /NDL (n = 4) tumors. Tumor cells were harvested from the most advanced tumor and used within four passages to ensure equal comparison. The expression of Muc4 was retained over this duration, as confirmed by immunocytochemistry (data not shown).
Anoikis assay
Primary NDL cells were plated at a density of 3 × 10 3 cells/ml in basal media in ultra-low adherence culture plates (Corning, Corning, NY, USA) for 24 h and viability in suspension conditions determined by trypan blue exclusion assay as described. 53 Blood cell co-culture suspension assays Blood was harvested from 8-12-week-old Muc4 wt (n = 6) or Muc4 ko mice (n = 6) via cardiac puncture, added to 3.8% sodium citrate (9:1) to prevent clot formation and centrifuged at~130 g for 10 min at room temperature. The upper fraction containing plasma, immune cells and platelets (plateletrich plasma) was re-centrifuged at~300 g to separate the cellular and plasma fractions. Blood cells were re-suspended in IMDM (Iscove's Modified Dulbecco's Media, Gibco) 54 with 10% FBS (blood cell fraction), combined with Muc4 wt /NDL or Muc4 ko /NDL cells at a ratio of 50-100:1, and cultured in ultra-low adherence conditions for 24 h. Controls included IMDM+10% FBS or IMDM+10% FBS/cell-free plasma.
Under ultra-low adherence conditions, NDL cells form small spheroids that are distinguishable from single white or red blood cells. For viability assays, tumor cells were pre-incubated with MitoFluor green (Molecular Probes, Waltham, MA, USA) for 30 min prior to co-culture to ensure their later discrimination from blood cells. MitoFluor green label retention was verified to extend beyond 36 h in NDL cells (data not shown) and was chosen for its capacity to effectively label all cells without adversely affecting viability. Within 30 min prior to concluding co-culture experiments, the entire culture was incubated with the vital nuclear stain Hoechst 33342 (Promokine, Heidelberg, Germany; ex. 350 nm/em. 461 nm) to detected nucleated immune and tumor cells, washed gently in PBS to remove unbound dye and stained with ethidium homodimer II (Promokine; ex. 528 nm/em. 617 nm) to identify dead/dying cells with poor membrane integrity. Non-nucleated platelets remained unstained. Spheres were pipetted onto microscope slides (Thermo), cover slipped and immediately imaged with an Olympus BX51 (Center Valley, PA, USA) fluorescence microscope fitted with a Nuance FX CRI camera.
For association assays, pooled NDL cells (n = 4/line) and blood cells were monitored and imaged at 1.5 h and 24 h on an Olympus IX81 microscope with Olympus cellSens Entry software. Interactions were considered to include the residence of any blood cell within close proximity (⩽5 μm) to a tumor cell. Time-lapse images of a single field were captured at 1 s intervals for 30-40 s.
Circulating tumor cell assay
Whole blood (~1 ml) was harvested as described above from mice injected at the lateral tail vein 3d prior with pooled NDL cells. Blood was immediately fixed in 4% paraformaldehyde for 2 h, centrifuged (~300 g) and washed in PBS. Nuclei were stained with 4',6-diamidino-2-phenylindole for 1 h at room temperature, plated on a glass microscope slide in a small volume of PBS and evaluated by fluorescence (tumor cells) and bright-field (blood cells) microscopy.
Transwell migration assay
Primary NDL cells were subjected to the transwell migration assay as described, 51 with some modifications. Cells were plated directly onto the transwell in serum starve media (0.1% FBS) at a density of 2.5 × 10 4 cells/ml and migration was permitted for 16 h. Migrated cells were fixed and stained with Diff-Quick staining solution (Dade Behring, Deerfield, IL, USA) prior to imaging with an Olympus IX81.
Statistics, data and image analysis
Values are expressed as mean ± s.d. For in vitro experiments, data represent at least three biological replicates preformed with a minimum of duplicate technical replicates. Data for in vivo studies reflect means of 4-6 (tail vein assays) or ⩾ 12 mice (genetic studies) per line. Cohorts were based on twosided power calculations (P = 0.05, 80% power) to detect differences in tumor growth/metastasis and are consistent with previous studies. 55, 56 Statistical significance was established using independent two-sided Student's t-test (with variance assumptions based on F-tests), Mann-Whitney U-test (non-linear values-immunohistochemistry, tumor burden and lung metastases) or log-rank test (survival curves) with P-valueso0.05 considered statistically significant. Data were analyzed with Microsoft Excel or R-statistical platform. Images were compiled in Adobe Photoshop with brightness, contrast and white balance modified only for clarity in print. Cell counting was performed using image J (NIH; http://rsb.info.nih.gov/ij/).
